Christopher R. Ensor

Summary

Christopher R. Ensor. Role: unknown. No source read in this review states the role of this author. Field: unknown. Affiliation: unknown (marked missing). Basis: unverified; OpenAlex lists "CareDx, Inc. (United States)" on the most recent corpus paper (2026). Not confirmed as current.. The whole-count rank depends substantially on consensus or guideline papers. Counts in the OpenAlex corpus (retrieved 2026-10-10): 18 papers and 1,292 citations over ten years; 4 first-author and 5 last-author papers. Ranks: main 15, excluding consensus papers 92, first or last author 19. The method is stated once on the People list page. Linked papers are the most-cited corpus papers of this author.

Citation ranks (10 years)

Citations: 1,292 in total, 340 excluding consensus and guideline papers (1 of this author's papers excluded), 258 on first or last author papers (4 first, 5 last).

Role and field

Role

unknown

Role status

unknown (no source read in this review states the role)

Field

unknown

Field basis

no unit name found in the sources read

Only what a cited source supports is stated. Entries marked self-asserted come from the person's own ORCID record. The field is taken from the name of the unit, not inferred from the person's name.

Details

papers 10y

18

fractional papers 10y

1.96

citations 10y

1292

fractional citations 10y

96.7

ranking retrieved

2026-10-10

orcid

0000-0003-0990-1406

openalex author id

A5085923859

merged open alex profiles

2

affiliation basis

unverified; OpenAlex lists "CareDx, Inc. (United States)" on the most recent corpus paper (2026). Not confirmed as current.

papers excluding consensus 10y

17

citations excluding consensus 10y

340

consensus papers excluded 10y

1

first author papers 10y

4

last author papers 10y

5

lead author citations 10y

258

lead author papers 10y

9

Sources and links

• ORCID record (primary)
• OpenAlex author profile (ranking source)
• Most-cited CLAD paper in corpus: Chronic lung allograft dysfunction: Definition, diagnostic criteria, and approaches to treatment―A consensus report from the Pulmonary Council of the ISHLT (The Journal of Heart and Lung Transplantation, 2019); 952 citations; DOI 10.1016/j.healun.2019.03.009
• Most-cited CLAD paper in corpus: Donor-specific antibody characteristics, including persistence and complement-binding capacity, increase risk for chronic lung allograft dysfunction (The Journal of Heart and Lung Transplantation, 2020); 36 citations; DOI 10.1016/j.healun.2020.09.003
• Most-cited CLAD paper in corpus: Rescue alemtuzumab for refractory acute cellular rejection and bronchiolitis obliterans syndrome after lung transplantation (Clinical Transplantation, 2017); 34 citations; DOI 10.1111/ctr.12899
• Most-cited CLAD paper in corpus: Effect of aerosolized antipseudomonals on Pseudomonas positivity and bronchiolitis obliterans syndrome after lung transplantation (Transplant Infectious Disease, 2017); 16 citations; DOI 10.1111/tid.12688
• Most-cited CLAD paper in corpus: Detrimental Association of Hypogammaglobulinemia With Chronic Lung Allograft Dysfunction and Death Is Not Mitigated by On-Demand Immunoglobulin G Replacement After Lung Transplantation (Progress in Transplantation, 2019); 10 citations; DOI 10.1177/1526924818817028

Related

Links from this record

• author: Chronic lung allograft dysfunction: Definition, diagnostic criteria, and approaches to treatment: A consensus report from the Pulmonary Council of the ISHLT

Known gaps in this record

• role or job title
• centre membership relation (not asserted)
• funding and conflicts of interest
• verified current affiliation
• whole-count rank depends substantially on consensus or guideline papers; see the rank excluding consensus papers
• whole-count rank depends substantially on consensus or guideline papers; see the rank excluding consensus papers